Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Adagene and City of Hope open small colorectal cancer study of two-drug combination

Adagene's muzastotug will be tested with ivonescimab in a study of up to 36 patients, but no financial or timing details were disclosed.

17 Nov 2026 · Adagene Inc. ADAG · Company news

Adagene and City of Hope said on 17 November 2026 that they have begun a small, academically led study of ivonescimab paired with Adagene's muzastotug (ADG126) in colorectal cancer. For Adagene, it extends the clinical footprint of muzastotug into a tumour type where the combination is now being tested in patients.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Adagene Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →